![]() We work with pharmaceutical companies to help them better develop new cancer treatments, understand the mechanism of action of these new drugs and ultimately propose targeted treatments for patients, i.e., achieve personalized medicine. ![]() INRIA has notably done a lot of work for the army concerning satellite images and missile guidance.įredrik Brag: Median’s business is focused on two extremely important areas: INRIA is the equivalent of the MIT Computer Lab or Stanford Lab in the United States, and it is one of the best computer science and artificial intelligence research laboratories in the world. I launched this company 20 years ago through a collaboration with INRIA, the French National Institute for Research in Computer Science and Control. Our company is based in Sophia-Antipolis, in the south of France, and includes 26 different nationalities. In short, with our technologies, we transform medical images into decisional insights to better diagnose, treat and monitor patients. MedicalExpo e-magazine: Can you tell us about your company and your main areas of technological development?įredrik Brag: Median Technologies deploys proprietary artificial intelligence, computer vision and signal processing technologies to develop imaging tests and services to better manage life-threatening diseases like cancer. We interviewed Fredrik Brag, CEO and founder of Median Technologies, to understand how he sees this solution as a real “paradigm shift” for early cancer diagnosis. Today, based on new results presented at the ECR concerning the performance of the iBiopsy® Lung Cancer Screening (LCS) Software as Medical Device, it is possible to determine whether a lung tumor found in a patient is cancerous or not with a sensitivity-ability to detect lesions and give a positive result when the patient is ill-of 96.5%, for a specificity-ability to give a negative result when the patient is not ill-of 97.2%. ![]() It enables the development of software as medical devices able to detect and characterize cellular information from CT images or other imaging modalities that cannot be seen by the naked eye. Median Technologies’ new medical imaging platform, iBiopsy®, integrates AI and machine learning technologies. Present at the 2023 European Congress of Radiology (ECR), the French company Median Technologies has developed a revolutionary technology that combines medical imaging and artificial intelligence (AI) to diagnose many types of cancers early and contribute to the emergence of new therapies tailored to the patient.
0 Comments
Leave a Reply. |